Introduction
Cancer killed 7.6 million people around the world in 2007. This number is expected to rise to 17.5 million by 2050. 1 The cancer treatments that are administered, surgery, radiation, chemotherapy, or biologic therapy, depend on the type and stage of cancer and other personal factors, such as age, health status, and individual preferences. Typically, surgery and radiation therapies are used to cure localized cancers. After a cancerous growth is removed through surgery, chemotherapy can considerably reduce the risk of cancer returning; chemotherapy is used not only to cure cancer, but also to slow its growth and to keep it from spreading.
Side effects associated with chemotherapy often result from the anti-cancer drugs' killing of healthy cells. Used most effectively, anti-cancer drugs should target cancer cells selectively using apoptosis-like mechanisms to maintain a patients' quality of life. Because cancer patients might have mutually different factors of tumor development, 2,3 a rapid, in vitro cell-based assay must be developed to verify the predicted efficacy of an anti-cancer drug quantitatively. Conventional methods for determining cell-survival-related cellbased assays are often time-consuming (2 -3 days) and require tedious luminescent and fluorescent labeling. [4] [5] [6] Furthermore, labeling might engender competitive interference, and thereby compromise the anti-cancer drugs' ability to function. 7 In an earlier study, we demonstrated a rapid and label-free quantitative evaluation method and instrument for apoptosis efficacy of anti-cancer drugs through a reaction analysis of living pancreatic cancer cells cultured on a sensor chip: a newly developed high-precision (50 ndeg s -1 average fluctuation) surface plasmon resonance (SPR) sensor. 8 At 35 min after the addition of an anti-cancer drug to the cell, the cell reaction was monitored for 5 min using differential SPR angle rates of change. It was related closely to cell viability. The differential SPR angle was independent of both the cell membrane potential and the cytosolic pH, but dependent on the inner mitochondrial membrane potential (ΔΨm) by simultaneous detections of the differential SPR angle change and fluorescence using specific probes and epi-illumination using the new instrument. The results are universally valid for various anti-cancer drugs of receptor binding type mediating apoptosis via the mitochondrial pathway through different cell-signaling by various pancreatic cancer cell lines containing personal factors of different levels of receptor and protein expressions. 9 Reportedly, the reduction of ΔΨm is significantly related to cell viability in the 20-h culture experiment. 10 This relation implies that the ΔΨm decrease might be an early apoptotic event, especially during treatment with certain cancer drugs. 11 However, in very early stages, no quantitative relation between the decreased rate of ΔΨm and cell viability has been reported in the relevant literature.
during the last decade, promising new targets have emerged from recent progress in apoptosis mechanisms. Among them, anti-cancer drugs that arrest the cell cycle have recently been of particular interest. [12] [13] [14] [15] [16] For example, roscovitine is an olomoucine-related purine flavopiridol in the stage of clinical trials, and is a highly potent and selective inhibitor for the kinase activity of cyclin-dependent kinases (CdKs): CdK1 (driving cell cycle of S/G2 phase transition, G2 phase progression, G2/M phase transition and M phase progression), CdK2 (G1/S transition, S progression), CdK5 (transcriptional regulation), and CdK7 (CdK1, 2 activation, transcriptional regulation), We propose a rapid and label-free quantitative evaluation of anti-cancer drug efficacy in apoptosis using live cancer cells cultured on a sensor chip. The resultant custom-made, high-precision surface plasmon resonance (SPR) sensor monitors the inner mitochondrial membrane's potential change (ΔΨm). For trans-membrane anti-cancer drugs to be effective, continuous potential changes arising from the crossing of the membrane by the drug of interest prevent ΔΨm monitoring. Herein, we report on a novel signaling echo method that avoids this disturbance; the cancer cells are incubated with a specific anti-cancer drug, with subsequent removal of the drug before SPR measurements. The cell reaction without any drug was monitored as the differential SPR angle rate of change for 10 min from 30 min after a sensor chip was set on a prism. The cell reaction after 60 min pre-incubation with a drug was significantly related to the conventional cell viability after 48 h (P <0.001). Original Papers but it does not work well for either CdK4 or CdK6 (G0/G1 transition). [17] [18] [19] [20] Roscovitine inhibits the kinase activity through competitive inhibition of ATP binding, arrests the cell cycle, and causes dNA fragmentation. In contrast, d-allose is a natural monosaccharide of rare sugar used as a chemopreventive food because of the development of industrial production methods for it. [21] [22] [23] Furthermore, this type of compound can be a new class of chemotherapeutic drug. Actually, d-allose induces apoptosis through G2/M cell cycle arrest, and up-regulation of CdK inhibitors of p21 (binding to CdK1 and CdK2) and p27 (binding to cyclin E-CdK2). These two anti-cancer drugs induce apoptosis via different mechanisms, but they each reportedly up-regulate the p53 protein level. 20, 22 The principal tumor-suppressor p53 protein plays a key role in cell cycle arrest and apoptosis in cancer cells. 12, 17, 18, 24, 25 In fact, p53 can both up-regulate genes, such as PUMA, Noxa, and p53AIP1, and down-regulate Bax to trigger transcriptional apoptosis; it can also directly translocate to the mitochondria preceding ΔΨm decrease and caspase activation to induce non-transcriptional apoptosis. 26, 27 However, anti-cancer drugs, such as those of the cell cycle arrest type, must pass through the cell membrane to function in the cell. They might therefore cause continuous cell membrane potential changes disturbing ΔΨm change measurements by the SPR. Furthermore, the differential SPR angle change reflects both changes in the cell membrane potential until around 30 min cell culture with a subsequent anti-cancer drug and in ΔΨm change. 8 These changes require a sampling time decision of the differential SPR angle change to evaluate the anti-cancer drug efficacy.
Development of Signaling Echo
This study investigates the signaling echo method ability using an SPR-based analytical platform for liver cancer cells treating either a trans-membrane (cell cycle arrest) type or non-trans-membrane (receptor binding into mitochondrial pathway) type of anti-cancer drug. We also confirmed that the signals related to apoptosis are retained in a cell using this method.
Experimental

Cancer cell culture
The human liver cancer cell line, Hep G2 (Health Science Research Resources Bank, Japan) was cultured with medium A (Eagle's minimum essential medium (EMEM) including 10% (v/v) fetal bovine serum (FBS), 89.7 μM penicillin, 68.6 μM streptomycin, and 100 μM each of nonessential amino acids (l-alanine, l-asparagine, l-aspartic acid, l-glutamic acid, glycine, l-proline, and l-serine)) in a chamber (37 C, 5% CO2, 91% humidity). Cancer cells in the log phase were rinsed once with phosphate-buffered saline including 9.86 mM phosphate, 137 mM NaCl, 2.68 mM KCl, 1.76 mM KH2PO4, and 8.10 mM Na2HPO4 at pH 7.3 (PBS) and were collected by resuspension in 0.05% (w/v) trypsin-0.02% (w/v) EdTA solution. Cell viability was assessed using a hemocytometer after trypan blue staining. Cancer cells were resuspended at a density of 2 × 10 6 cells ml -1 ; 100 μl of slurry was spotted on a sensor chip to culture for 18 h in the chamber for the measurement of SPR, immunofluorescence, and fluorescence. All chemicals, except for FBS (Sigma, St. louis, MO) were purchased from Wako Pure Chemical Industries ltd., Japan.
Cell viability assay
The cancer cells were resuspended at a density of 5 
High-precision SPR system
A custom-made high-precision SPR used to monitor the difference in SPR angle changes between a sensing spot with cancer cells and a reference spot without cancer cells is a Kretschmann configuration. The p-polarized light beam is a diode laser of 670 nm (3 mW) with a beam diameter of 1 mm to measure 1000 cells. It is split into reference and sensing beams to pass a BK7 plano-cylindrical lens. The reflected light beams were detected using silicon photodiodes. The sensor chip placed on the prism using a refractive index matching liquid was kept at 37.0 ± 0.1 C. Once the SPR angle was decided for the cancer cells by the scanning angle, the change derived from the cell reaction by an anti-cancer drug was monitored at the negative side angle equal to 2/3 of the dip depth without an angle scan. 28 The high-precision SPR was set under the cancer cells with a fluorescence microscope over the cancer cells to monitor both the SPR angle and the fluorescence intensity simultaneously. A fluorescence microscope (Axioplan 2; Carl Zeiss Inc., Germany) was combined with a charge-coupled detector (MicroMAX-512BFT; Princeton Instruments, Inc., Trenton, NJ). The light source was a 75-W xenon lamp (Carl Zeiss Inc., Germany).
SPR measurement
The cells on the sensor chip (a 1-mm-thick BK7 slide glass covered by a 50-nm-thick gold film) were rinsed with EMEM containing 0.1% (v/v) dMSO. For the standard method, the sensor chip was rinsed with PBS and set on the SPR instrument, with subsequent filling with 5 ml EMEM containing 0.1% (v/v) dMSO. After 20 min, the medium was replaced with 5 ml EMEM containing an anti-cancer drug. For the signaling echo method (Fig. 1) , the sensor chip was incubated with 100 μl EMEM containing one anti-cancer drug and dMSO in the same manner in cell viability assay for 30, 45, or 60 min in Fig. 1 Schematics of signaling echo method for high precision SPR system. the chamber. The sensor chip with cancer cells was rinsed with PBS and set on the SPR instrument, followed by filling with 5 ml EMEM containing 0.1% (v/v) dMSO. The differential SPR angle change (sensing-reference) was monitored for 50 min at 1 s intervals.
The refractive index of high-precision SPR was calibrated by a series of sucrose (Nakalai Tesque Inc., Japan) solutions with known refractive indices.
29,30
Immunofluorescence measurement for p53 and fluorescence measurement for ΔΨm
The cells on a sensor chip were rinsed with EMEM containing 0.1% (v/v) dMSO and incubated with 100 μl EMEM containing 0 or 50 μM roscovitine, or 0 or 50 mM d-allose, and 0.1% (v/v) dMSO for 60 min in the chamber. For p53 protein, a p53 detection kit containing antibodies (Thermo Scientific Cellomics Inc., Pittsburgh, PA) was performed for the cancer cells on the sensor chip after 60 min left on the SPR system, as follows. The cancer cells on the sensor chip were rinsed with dulbecco's PBS (Wako Pure Chemical Industries ltd., Japan), fixed with 5% paraformaldehyde (Wako Pure Chemical Industries ltd.) in dulbecco's PBS for 15 min and permeabilized with 1% Triton X-100 for 15 min at room temperature. The sensor chip was blocked for 60 min in 5% normal goat serum in dulbecco's PBS at room temperature. The sensor chip was then incubated overnight with p53 primary antibody at 4 C, followed by incubation with secondary Alexa Fluor 488 conjugated goat anti-mouse IgG for 60 min at room temperature. For ΔΨm, 3 μl EMEM containing 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl benzimidazol carbocyanine (JC-1) iodide (Enzo life Sciences Inc., San diego, CA) and 0.1% (v/v) dMSO were added to the medium 20 min before the end of the culture. After culturing in the chamber, they were treated identically as in the SPR measurement using a signaling echo method. Fluorescence corresponding to p53 and ΔΨm was monitored with excitation at 485 ± 20 nm and fluorescence at 540 ± 25 nm, and with excitation at 485 ± 20 nm and fluorescence at 610 ± 30 nm, respectively, using a fluorescence microscope with software (MetaFluor Imaging System 4.6.5; Universal Imaging Corp., West Chester, PA).
Statistical analysis
Two-tailed ANOVA was performed using software (SPSS 11.0 J or 16.0 J; SPSS Inc., Chicago, Il).
Results and Discussion
Cell viability assay
For a comparison with the SPR results, conventional cell viability assay was performed against anti-cancer drugs of trans-membrane (cell cycle arrest) type, roscovitine and d-allose, and of non-trans-membrane (receptor binding into mitochondrial pathway) type, trans-resveratrol (Fig. 2) . As presented in Fig. 3 , the cell viability depended on each anti-cancer drug's concentration, as described in previous reports.
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Signaling echo method
The differential SPR angle change is shown for roscovitine at concentrations of 0, 25.0, or 50.0 μM using a standard method, shown in Fig. 4a . The differential SPR angle decreased with time. drug efficacy prediction using a standard method is difficult because the positive differential SPR angle rate of change obtained using the standard method is negatively related to cell viability, as described in a previous work. 8 Additionally, a cyclical interaction will exist between the cell membrane and roscovitine because some small waves are recognized from a trend of the SPR angle change. This fact implies that the continuous cell membrane change caused by roscovitine crossing the cell membrane disturbs the monitoring of ΔΨm. Furthermore, an incubation time of at least 30 min is necessary for effective penetration of the drug via the cell membrane into the cytosol, as demonstrated previously in mitochondria depolarization experiments related to monitoring the effect of carbonyl cyanide 3-chlorophenylhydrazone administration. 8 Based on those results, to minimize the interaction between the cell membrane and an anti-cancer drug, we nominated the pre-incubation of cancer cells with a drug and removal of the anti-cancer drug before SPR measurements. However, the cell retained the apoptosis signal in the cell (signaling echo method). An examination of the pre-incubation time using roscovitine 25.0 μM is depicted in Fig. 4b . After 60 min of pre-incubation, an increase of the SPR angle change, indicating the decrease of ΔΨm, was observed along with an increase in the measurement time. At the beginning of the SPR measurement, the trend of the SPR angle change was not often constant, possibly because of a lag of the cell temperature rise to 37.0 C, because we transferred an SPR sensor chip onto a prism from an incubator kept at 37.0 C. Therefore, we devoted attention especially to any differential SPR angle change after 30 min of setting a sensor chip set on a prism.
The penetration depth of conventional SPR is limited to about 100 nm. 31 The ΔΨm of all mitochondria in a cell was observed by SPR: simultaneous fluorescence observation by an epi-illumination using JC-1 iodide equaled the results obtained using SPR in our previous study. 8 In a cell, several hundred mitochondria exist with heterogeneity in ΔΨm. 32 We measured about 1000 cells using SPR. 8 Because heterogeneity exists among cells, 32 the field range can be enhanced to 50 -80 times that of conventional SPR in the surface plasmon field-enhanced fluorescence spectroscopy. 33 This enhancement is also possible for absorbing a dielectric medium on the gold. 34 Mitochondria are sufficiently close to connect with other organelles, including the cell membrane, which contacts with gold. The mitochondria are sufficiently close to form a network. 35 Furthermore, a mitochondrial electrochemical network exists through Ca 2+ flux or oscillation, creating the strong magnetic field. 36 The magneto-optic activity of magnetic materials enhances the SPR sensitivity. 37 Based on those results of earlier studies, we infer that the evanescent field can reach all mitochondria in a cell. Additional studies are being conducted to confirm this point.
Determination of signal retention
Roscovitine and d-allose induce apoptosis via different mechanisms, as described above, although they both might up-regulate the p53 protein level. 18, 21 Based on that fact, the p53 accumulation by anti-cancer drugs was determined to confirm the signal retention to the ΔΨm change for the signaling echo method, because Hep G2 has a wild-type p53 protein. 18 As portrayed in Fig. 5 , the accumulation of p53 was observed in both anti-cancer drugs after 60 min of the drug removal. Moreover, the signal retention to ΔΨm was confirmed.
We next examined the signal retention of ΔΨm using specific fluorescence dye, JC-1 iodide. 38 Figure 5 shows that a decrease in the fluorescent intensity, indicating a decrease in ΔΨm, was observed after 50 min of drug removal. Consequently, a decrease in ΔΨm was observed in this experiment. We were encouraged that our high-precision SPR system with a signaling echo method could evaluate the efficacy of trans-membrane (cell cycle arrest) type anti-cancer drugs in a very early stage of apoptosis, as described in our previous report. 8 
Relation between the differential SPR angle rate of change and cell viability assay
The differential SPR angle changes found by the signaling echo method are shown in Fig. 6 for roscovitine and d-allose at 60 min post incubation. The differential SPR angle rate of change, expected to be related to results from the cell viability assay, depended on the anti-cancer drug concentration. The rate of increase of the differential SPR angle change sampled for 10 min after 30 min of a sensor chip set on a prism was significantly related to cell viability among various concentrations of drugs with trans-membrane (cell cycle arrest) and non-trans-membrane (receptor binding into mitochondrial pathway) types together with r = 0.928 (P <0.001), as depicted in Fig. 7 . Because necrotic cells were peeled off from the sensor chip, these results strongly suggest that the SPR can evaluate the apoptotic efficacy of liver anti-cancer drugs quantitatively. Here, the SPR response as the differential angel change equaled to 7.0 × 10 -3 refractive index units (RIU) deg -1 . This means that the change of 10 -9 magnitude of RIU s -1 was measured for 10 min using about 1000 cancer cells for a lower anti-cancer drug efficacy evaluation. Roscovitine and d-allose induce apoptosis via different cell cycle arrest mechanisms, as described previously. Furthermore, the mode of action of trans-resveratrol differs from that of cell cycle arrest type anti-cancer drugs because it binds to epidermal growth factor and/or estrogen receptor to induce apoptosis via mitochondrial pathway. [18] [19] [20] The obtained results are universally valid for various anti-cancer drugs that mediate apoptosis through different cell-signaling pathways.
Conclusions
We established a signaling echo method to achieve rapid and label-free cell-based quantitative screening of anti-cancer drugs in apoptosis without drug presence for high-precision SPR. Using this method, we avoid the disturbance of continuous potential changes, which prevents the monitoring of ΔΨm, arising from a crossing of the membrane by the drug of interest. The result was achieved by incubating cancer cells with a specific anti-cancer drug for 60 min, with a subsequent removal of the drug before the SPR measurement. We confirmed this achievement using trans-membrane (cell cycle arrest) and non-trans-membrane (receptor binding into mitochondrial pathway) types of anti-cancer drugs involving potential targets for anti-cancer drug candidates designed to target specific cell-signaling pathways. 39 Additionally, the signals to ΔΨm and ΔΨm changes were confirmed as retained in the cell, even 50 min after drug removal. Our system is a universally valid assay for various anti-cancer drugs. It will lead to an ability to quickly and effectively evaluate a patient's personal therapeutic potentials of apoptosis-inducing anti-cancer drugs using liver cancer cells. 
